---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024215"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:36:04.365469+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics Q3 2022 net loss $29.1M; cash $393.3M; pipeline advances

## Summary
- Net loss $29.1M ($0.33/share) vs $19.6M ($0.28) year ago; cash $393.3M sufficient into 2025.
- TNG908 phase 1/2 trial enrolling; CTA approved in France; initial safety and efficacy data expected H1 2023.
- Disclosed TNG260 as CoREST inhibitor for STK11-mutant cancers; IND filing on track for H1 2023.
- Declared TNG348 development candidate for BRCA1/2-mutant cancers; IND filing planned for 2023.
- Appointed Aaron Weitzman as CMO; R&D expenses $28.7M, G&A $8.1M.

## SEC filing metadata
- accession: 0000950170-22-024215
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000095017022024215/0000950170-22-024215-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000095017022024215/tngx-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024215
- JSON: https://secwatch.observer/filing/0000950170-22-024215.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024215.txt

## Key facts
- Earnings Releases
  Tango Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $6.9 million.
  - Period: third quarter ended September 30, 2022
  - Revenue: $6.9 million
  - Result: reported results
  source text: held $393.3 million in cash, cash equivalents and marketable securities, which the Company believes to be sufficient to fund operations into 2025. Collaboration revenue was $6.9 million for the three months ended September 30, 2022, compared to $6.8 million for the same period in 2021, and $18.4 million for the nine months ended September 30, 2022 compared to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000095017022024215/0000950170-22-024215-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.